Transmucosal Drug Delivery Systems Market Growth, Size 2031

Transmucosal Drug Delivery Systems Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By System (Nasopulmonary, Buccal & Sublingual, Vaginal, and Others), End User (Healthcare facilities, Homecare Settings, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

Publication Month : Mar 2024

  • Report Code : TIPRE00004209
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Inquire Before Buy

PRICING

$5190

$4671

[Research Report] The transmucosal drug delivery systems market size is expected to grow from US$ 80.21 billion in 2023 to US$ 129.46 billion by 2031; it is estimated to register a CAGR of 6.2% from 2023 to 2031.

Analyst Viewpoint

Transmucosal drug delivery involves mucosal membranes such as oral mucosa, nasal mucosa, rectal mucosa, vaginal mucosa, ocular mucosa, and pulmonary mucosa for drug administration. Higher bioavailability, rapid onset of action, evasion of first-pass metabolism, and ease of administration are the key advantages of this drug delivery system over traditional routes of drug administration. The report includes growth prospects owing to the current transmucosal drug delivery systems market trends and their foreseeable impact during the forecast period.

Factors Driving Transmucosal Drug Delivery Systems Market Growth

Transmucosal drug delivery is a preferred route of drug administration owing to the sustained efficacy of this type of delivery. Transmucosal routes such as intranasal, buccal, sublingual, and rectal are noninvasive methods of the systemic delivery of drugs. They are particularly useful as caregivers or patients can administer these drugs without the need for expert personnel. Moreover, a rapid onset of action with reduced first-pass metabolism makes them ideal for palliative and end-of-life care. They work fast to relieve symptoms and offer patients quick relief. As a result, transmucosal delivery systems have become a popular choice in the management of various chronic diseases, such as cardiovascular diseases, diabetes, and chronic respiratory diseases. As per an article published by PubMed Central in January 2020, a study was carried out for the investigation and comparison of the safety and pharmacokinetics of dihydroergotamine (DHE) when administered in the form of intranasal DHE powder (STS101), intranasal DHE spray (Migranal), and intramuscular (IM) DHE injection in healthy subjects. The study concluded that STS101 is an easy-to-administer, non‐injected, acute treatment for migraine with a favorable tolerability profile. It is further expected to facilitate rapid and consistent pain relief, and suppress migraine symptoms without recurrence.

Numerous pharmacological drugs are offered as oral transmucosal formations; these include cardiovascular agents, sedatives, and analgesics. Biodegradable oral films aid in drug delivery to the systemic circulation, which is highly advantageous for individuals with dysphagia, repeated vomiting, hypertension, heart attack, asthma, nausea, paralysis, and mental disorders. These oral fast-dissolving films are thin adhesive strips that are placed on the patient's tongue or any oral mucosal tissue.

Therefore, advantages such as ease of administration, high bioavailability, systemic drug availability, and rapid action fuel the transmucosal drug delivery systems market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Transmucosal Drug Delivery Systems Market: Strategic Insights

transmucosal-drug-delivery-systems-market
Market Size Value inUS$ 80.21 billion in 2023
Market Size Value byUS$ 129.46 billion by 2031
Growth rateCAGR of 6.2% from 2023 to 2031
Forecast Period2023-2031
Base Year2023
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope

The "Global Transmucosal Drug Delivery Systems Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on global market trend analysis. The report aims to provide an overview of the market with detailed market segmentation based on systems, end user, and geography. It provides key statistics on the leading market players as well as mentions key trends and opportunities prevailing in the market. The scope of the global transmucosal drug delivery systems market report entails North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

 

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Systems-Based Insights

Based on systems, the market is segmented into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held the largest transmucosal drug delivery systems market share in 2023 and is anticipated to register the highest CAGR from 2023 to 2031.

End User-Based Insights

Based on end user, the market is segmented into healthcare facilities, homecare settings, and others. The healthcare facilities segment held the largest market share in 2023. This can be attributed to the availability of better facilities and skilled physicians in hospitals. Further, the homecare settings segment is anticipated to hold the highest CAGR from 2023 to 2031.

Transmucosal Drug Delivery Systems Market, by End User – 2023 and 2031

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Regional Analysis

Based on geography, the market is primarily segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. In terms of revenue, North America held the largest transmucosal drug delivery systems market share in 2023. The US dominates the market in this region. This can be attributed to the increasing cases of chronic diseases such as diabetes, asthma, and cardiac diseases as well as the growing number of product launches by key players.

Industry Developments and Future Opportunities:

The transmucosal drug delivery systems market forecast can help stakeholders in this marketplace plan their growth strategies. As per company press releases, a few strategic developments by leading players operating in the global market are listed below:

  • In February 2024, Aquestive Therapeutics, Inc. presented a poster at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 annual meeting in Washington, DC, highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two complete clinical studies on sublingual Anaphylm (epinephrine) film.
  • In August 2022, iX Biopharma Ltd launched IXB-322, a new program to expand its pipeline. The program aims to develop a sublingual dexmedetomidine wafer for the treatment of agitation in dementia and other indications. This initiative is part of iX Biopharma's strategy to repurpose existing approved drugs using its proprietary WaferiX drug delivery platform technology.
  • In May 2021, Tillotts Pharma AG, a part of the Japanese Zeria Group, added a new medication to its gastroenterology portfolio with the launch of AsacolTM 1g (mesalazine). The high-strength suppository is used to treat mild to moderate ulcerative proctitis symptoms in adults. This launch will help the company offer innovative therapies to patients with gastrointestinal diseases. AsacolTM 1g suppositories provide a convenient form of treatment for individuals suffering from ulcerative proctitis, as they only require a single daily dose.
  • In April 2021, Teva Pharmaceuticals USA, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd., announced the release of its generic version of Casana 1 (mesalamine) suppository medicine. The medicine is indicated for the treatment of active ulcerative proctitis (ulcerative rectal colitis) in the US.

Teva Pharmaceutical Industries Ltd; Cigna Corporation.; BioDelivery Sciences International, Inc; 3M; Henkel Finland Oy; GlaxoSmithKline plc; Aquestive Therapeutics, Inc; Camurus AB; Ximedica; and Noven Pharmaceuticals, Inc are a few of the key companies profiled in the transmucosal drug delivery systems market report. These leading players focus on expanding and diversifying their market presence and clientele, tapping business opportunities in the market.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

System, End User, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are transmucosal drug delivery systems?

The transmucosal drug delivery involves mucosal membranes such as oral mucosa, nasal mucosa, rectal mucosa, vaginal mucosa, ocular mucosa, and pulmonary mucosa for drug administration. Higher bioavailability, rapid onset of action, evasion of first-pass metabolism, and ease of administration are the key advantages of this drug delivery system over traditional routes of drug administration.

What factors drive the transmucosal drug delivery systems market?

Key factors driving the transmucosal drug delivery systems market growth is rising adoption of drug delivery systems for disease management and the development of new drug molecules and biological formulations.

What was the estimated transmucosal drug delivery systems market size in 2023?

The transmucosal drug delivery systems market was valued at US$ 80.21 billion in 2023.

Who are the major players in the transmucosal drug delivery systems market?

The transmucosal drug delivery systems market majorly consists of the players, including Teva Pharmaceutical Industries Ltd; Cigna Corporation.; BioDelivery Sciences International, Inc; 3M; Henkel Finland Oy; GlaxoSmithKline plc; Aquestive Therapeutics, Inc; Camurus AB; Ximedica; and Noven Pharmaceuticals, Inc.

What are the growth estimates for the transmucosal drug delivery systems market till 2031?

The transmucosal drug delivery systems market is expected to be valued at US$ 129.46 billion in 2031.

Which system segment dominates the transmucosal drug delivery systems market?

The transmucosal drug delivery systems market, by systems, is bifurcated into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held a larger market share in 2023.

The List of Companies - Transmucosal Drug Delivery Systems Market

  1. Teva Pharmaceutical Industries Ltd
  2. Cigna Corporation
  3. BioDelivery Sciences International, Inc
  4. 3M
  5. Henkel Finland Oy
  6. GlaxoSmithKline plc
  7. Aquestive Therapeutics, Inc
  8. Camurus AB
  9. Ximedica
  10. Noven Pharmaceuticals, Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Transmucosal Drug Delivery Systems Market